PCSS-MOUD Clinical Roundtable: Clinical Considerations for 7-OH and High-Potency Kratom Derivatives-Roundtable Slides for Download

Roundtable Slides for Download

Pdf Summary

This presentation reviews emerging clinical issues related to high‑potency “kratom” derivatives—especially products containing synthetic 7‑hydroxymitragynine (7‑OH) and mitragynine pseudoindoxyl (MP, sometimes marketed as “Red‑OH”). While whole‑leaf kratom has centuries of use in Southeast Asia and, in the U.S., is used by an estimated 2–5 million people annually (often for energy, pain, or self-treatment of OUD/AUD), newer concentrated extract and isolated/synthetic alkaloid products have increased opioid-like risk. The FDA currently advises against kratom use and, by 2025, warned that 7‑OH products can cause serious harm. The market has rapidly evolved: extracts emerged around 2020, highly concentrated synthetic 7‑OH/MP products became common in 2023–24, and even more potent derivatives (e.g., MGM‑15, MGM‑16) appeared in 2025.<br /><br />A key theme is that “product form and concentration” drive risk. Whole‑leaf kratom is a complex mixture of ~40 alkaloids with activity across opioid, adrenergic, serotonergic, and other systems, producing relatively weak μ‑opioid receptor (MOR) effects overall. Mitragynine is most abundant; 7‑OH is a minor constituent and can also form in vivo. By contrast, isolates/extracts can deliver high alkaloid exposures, are often poorly labeled, and may include potent opioid-active constituents; MP is described as a very potent MOR full agonist. Risks rise further with polysubstance use, adulteration/contamination, and potential CYP drug interactions.<br /><br />The speakers outline assessment and management strategies: obtain detailed product/dose/frequency and co-use history; use toxicology testing thoughtfully; distinguish OUD from other substance use disorders; and use shared decision-making. Treatment options include withdrawal management (buprenorphine or adjunctive meds), relapse prevention with oral or XR naltrexone, and buprenorphine induction approaches similar to short‑acting opioid protocols (precipitated withdrawal is considered uncommon). Patient education on overdose risk—especially with polysubstance exposure—is emphasized. A telehealth program chart review (NY/PA) found rising kratom/7‑OH use among buprenorphine initiators and suggested good treatment retention in this group.

Keywords

high-potency kratom derivatives

7-hydroxymitragynine (7-OH)

mitragynine pseudoindoxyl (MP)

synthetic kratom alkaloids

kratom extracts and isolates

mu-opioid receptor agonism

opioid-like overdose risk

FDA kratom warning 2025

kratom withdrawal management

buprenorphine induction and retention